Pfizer Inc. is looking to sell its remaining stake in Covid-19 vaccine partner BioNTech SE, a remnant from one of the ...

Pfizer Inc said on Thursday it sold a part of its stake in German drugmaker BioNTech SE , more than five years after both ...

BioNTech said on Thursday that its collaboration with Pfizer has not changed, when asked to comment on a report that Pfizer ...

A BioNTech spokesperson downplayed the news, insisting that the two companies remain “close” and have a “strong collaboration ...

A significant development emerged on November 13 when Pfizer announced it had sold 54.7% of its stake in BioNTech, retaining only $163.5 million worth of shares. This move marks a substantial shift in ...

SC lawmakers advanced a bill that would require a disclaimer for COVID-19 vaccinations. Physicians have broadly encouraged ...

Pfizer sell 508M stake in BioNTech through an overnight block trade, marking its exit from the COVID-19 vaccine partner's equity.

BioNTech formally launched its public takeover bid on October 22, 2025, offering CureVac shareholders approximately $5.46 per share in BioNTech American Depositary Shares. The exchange ratio includes ...

BioNTech, a biotech company best known for its successful development of a messenger RNA Covid-19 vaccine, is acquiring fellow mRNA company CureVac in a $1.25 billion stock deal that brings together ...

BioNTech is bolstering its artificial intelligence and machine learning capabilities through the £362 million acquisition of InstaDeep, a startup whose technology has already supported the company’s ...

BioNTech CEO Ugur Sahin is taking a big pay cut in 2021, but his large stake in the German company he co-founded still qualifies him for billionaire status. Sahin received a pay package worth 11.59 ...

[NEW YORK] Pfizer is looking to sell its remaining stake in Covid-19 vaccine partner BioNTech, a remnant from one of the ...